PRESS-RELEASE ·Filed Jun 19, 2026

CAMP

CAMP4 Therapeutics
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release: activist
Actionable Insight • Neutral

This is a routine inducement grant with no trading signal. Monitor for pipeline catalysts (clinical data readouts, regulatory milestones) which are the primary value drivers for CAMP. The next material event would be a Phase 1/2 data release or financing announcement.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CAMP ▼ -0.24% at T+60d
NEUTRAL call ✗ call lost -0.24% · α vs SPY -1.98% · entry $4.20 → $4.19
Entry anchored
Jun 18, 03:59 PM ET
via exchange tick
T+1d
+3.81%
call +3.81% · α +5.26%
$4.36
settled 3mo ago
T+5d
0.00%
call 0.00% · α +2.07%
$4.20
settled 3mo ago
T+20d
-11.67%
call -11.67% · α -11.52%
$3.71
settled 2mo ago
T+60d
-0.24%
call -0.24% · α -1.98%
$4.19
settled 17d ago

Price Chart

Loading chart...

Executive Summary

CAMP4 Therapeutics granted inducement stock options for 39,000 shares to three new hires at $3.96 per share, a routine compensation event for a clinical-stage biotech. The filing contains no financial results, pipeline updates, or regulatory catalysts, making it immaterial for trading purposes.

Key Facts

  • Inducement grants of 39,000 non-qualified stock options to three new employees
  • Exercise price of $3.96 per share, equal to closing price on June 15, 2026
  • Options vest over four years with 25% cliff at one year
  • Granted under the 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4)

Financial Impact

Minimal — 39,000 options represent ~0.2% of outstanding shares (assuming ~20M shares outstanding based on $214M market cap at $3.96). No cash impact.

dilution

Risk Factors

  • No financial or pipeline data in this filing — stock moves on clinical catalysts, not compensation grants
  • Historical performance shows poor T+20 outcomes on neutral calls (avg -3.47% T+20), but this filing has no directional content

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3314891
13 reports for CAMP
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+1▲ +49.40%Mar 5, 2026
Filters
Rows
Reports for CAMP — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Press Release
NEUTRAL ★ 4/10
$4.34 $4.03▼ −7.14%▼ −6.64%$3.73 (−13.95%)
Sep 2, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$4.49 $4.25▼ −5.35%▼ −4.20%$3.73 (−16.83%)
Aug 21, 2026
6w ago
Insider Cluster
BEARISH ★ 4/10
$4.48 $4.15▲ +7.37%▲ +7.84%$3.73 (+16.64%)
Aug 13, 2026
7w ago
EFFECT
NEUTRAL ★ 3/10
$4.50 $4.45▼ −1.11%▲ +0.85%$3.73 (−17.01%)
Aug 5, 2026
8w ago
Insider Cluster
BULLISH ★ 8/10
$4.50 $4.50· 0.00%▼ −1.21%$3.73 (−17.01%)
Aug 5, 2026
8w ago
Insider Cluster
BULLISH ★ 8/10
$4.50 $4.50· 0.00%▼ −1.21%$3.73 (−17.01%)
Jul 27, 2026
9w ago
8-K
MIXED ★ 6/10
$3.42 $3.45▲ +0.88%▼ −0.20%$3.73 (+9.20%)
Jun 19, 2026
14w ago
Press Release
NEUTRAL ★ 2/10
$4.20 $4.20· 0.00%▲ +2.07%$3.73 (−11.08%)
Jun 12, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$3.96 $4.20▲ +6.06%▲ +7.44%$3.73 (−5.69%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$4.22 $4.14▼ −1.90%▼ −2.33%$3.73 (−11.50%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 19, 2026